If Juvenescence puts serious effort into senolytics, then this will be useful. The more the merrier in that field to join Unity Biotechnology, Oisin Biotechnolo

If Juvenescence puts serious effort into senolytics, then this will be useful. The more the merrier in that field to join Unity Biotechnology, Oisin Biotechnologies, SIWA Therapeutics, etc. Everything else outside the SENS portfolio that can be accomplished via drug discovery to alter the operation of metabolism, focusing on known targets such as mTOR, is most likely a pointless waste of time and energy. It has been a pointless waste of time and energy for the past two decades, and I don't see that changing any time soon. The approach of trying to mimic calorie restriction or upregulate autophagy or mess with growth hormone/insulin metabolism or mimic exercise has very definite upper bounds on effectiveness. The longevity dividend promise of "spend billions to add a couple of years of life expectancy by 2040" is underwhelming, and anyone out there talking about drug discovery to alter metabolism to slow aging is in that camp. If billions are to be spent, then use them to follow the SENS approach of damage repair, not tinkering the system to slightly slow down the pace of damage accumulation. Only damage repair, such as via senolytics to clear senescent cell accumulation, can in principle produce rejuvenation of the old and greatly extended healthy life spans, more than just a few years. It is not a coincidence that senescent cell clearance has in a few short years, just as soon as people started to try it in earnest, proven itself far more effective and reliable and useful than the past 20 years of people trying to mimic calorie restriction or boost autophagy.